The Form 4 filing, an SEC report of insider stock transactions, was filed on November 13, 2026. Both sales took place on November 11, 2026, two days before the filing date. The record covers one director and one filing.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-11 |
| Date of Latest Transaction | 2026-11-11 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 500,000 |
| Price | $150.38 |
| Total Transaction Value | $75,190,000.00 |
| Insider | |
| Ticker Symbol | MANE |
| Company | Veradermics, Inc |
| Insider Name | ENRIGHT PATRICK G |
| Insider Title | Director |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 1,803,474 |
| Position Size Change | 21.71% |
| Filing | |
| Filing Date | 2026-11-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of Veradermics (MANE) shares, reported under transaction code S. Director Patrick G. Enright reported two sale transactions in the filing.
What was the average price of the transaction?
The average sale price was $150.38 per share across the two transactions. The available details do not list a separate average price for each sale.
How did this transaction affect the insider's holdings?
The sales reduced Patrick G. Enright's reported holdings by 500,000 shares, leaving 1,803,474 shares afterward. The shares sold made up 21.71% of the shares held before the sales. He continued to report owning shares after these transactions.
What's the total transaction value?
The total reported value was $75,190,000.00 for both sales combined. The available details do not break that total into separate dollar values for each sale.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Footnote text was not available, so further terms or explanations for the sales remain unknown. The reported figures do not establish why the shares were sold.
For research purposes only; not investment advice.